The News In Depth

Attention Heightens on Creating an Independent Regulatory Pathway for Introducing Novel Excipients

Drawing increasing attention in the global industry/regulator dialogue is the need for excipients that are fit-for-purpose in meeting the complex challenges of formulating, manufacturing, and delivering the new generation of medicines and making them as safe, efficacious, and patient- and distribution-friendly as possible.

February 17, 2020 | Posted in The News in Depth | Read More »

IPQ Monthly Update – December 2019 in Review

The December issue explores the collaborative efforts in which industry and regulators are now engaged to address the challenges of assuring the quality and availability of medicines across an increasingly globalized supply chain. The first story reviews various components of the progress that is being made in inspection-related information, standards and resource sharing – with a focus on the US and Europe, in particular – while the second shifts the focus to the Southeast Asia regional efforts going on through ASEAN.

January 23, 2020 | Posted in The News in Depth | Read More »

US/EU MRA Implementation, US Congressional Hearings, and Industry Surveys Shed Light on Global GMP Inspection Challenges and Collaboration Opportunities

During the past decade, industry and regulators around the world have been heavily focused on addressing the daunting challenges of assuring the quality of medicines across an increasingly globalized supply chain.

January 15, 2020 | Posted in The News in Depth | Read More »

International Mutual Inspection Recognition Expands with ASEAN Accrediting Philippines Using PIC/S Criteria

The FDA Philippines (FDAP) has been approved to join the regulatory agencies of Singapore, Malaysia, Indonesia, and Thailand on the Association of Southeast Asian Nations (ASEAN) Listed Inspection Services (LIS), after an extended review process that included documentary, on-site, and in-process inspection assessment.

December 29, 2019 | Posted in The News in Depth | Read More »

IPQ Monthly Update – November 2019 in Review

In this issue, IPQ explores the prominent FDA and industry association initiatives that are active in the quality metrics and culture arena – how they are progressing, how they interrelate, their impact, and the learnings they are providing. The first story focuses on the initiatives taking place on the pharma side, while the second shifts to the implementation of the Center for Devices' highly relevant Case for Quality and voluntary improvement pilot programs.

December 23, 2019 | Posted in The News in Depth | Read More »

CDRH Case for Quality Voluntary Improvement Pilot Collaboration Shows Impressive Results for Device Manufacturers

FDA’s Center for Devices and Radiological Health (CDRH) expects to fully implement its “Voluntary Manufacturing and Product Quality” program in 2020, following a positive experience during the pilot phase of this highly collaborative alternative to traditional agency inspections.

December 19, 2019 | Posted in The News in Depth | Read More »

FDA and Industry Quality Metrics Initiatives Are Paving for Way to Manufacturing and Regulatory Advancements

Three FDA quality metrics initiatives – involving site visits, industry feedback, and academic research – are expanding the understanding of how metrics can be most effective in advancing pharmaceutical quality and culture and preventing process failures and product shortages, while streamlining regulatory oversight.

December 12, 2019 | Posted in The News in Depth | Read More »

IPQ Monthly Update – September/October 2019 in Review

The issue begins with an exploration of how USP is evolving its standard setting approach for the new generation of biologic products and processes, and follows with a complementary review of the challenges in raw material and excipient use in biologics, in particular. The next two stories focus on the regulator and industry learnings, respectively, in gaining experience with the unique considerations that cell and gene therapies present in facility and operation management.

November 13, 2019 | Posted in The News in Depth | Read More »

Industry Experience with Autologous Cell Therapies Underscores Need for Upfront Planning on Integrating Facility Design, Operations, and Supply Lines

Industry experience with autologous cell therapies is matching up with that of regulators in underscoring the importance of comprehensive integrated planning – encompassing internal operations and facility design as well as the complexities of the supply chain – to be able to meet future capacity needs.

November 8, 2019 | Posted in The News in Depth | Read More »

The Processing and Formulation Complexities of Therapeutic Biologics Compel Heightened Focus on Excipient Needs

The processing and formulation complexities of the new generation of therapeutic biologics are compelling industry and regulators to take a hard look at the risks and requirements of the raw materials and excipients involved.

November 5, 2019 | Posted in The News in Depth | Read More »